Literature DB >> 10716082

TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment.

F Karpati1, F L Hjelte, B Wretlind.   

Abstract

Proinflammatory cytokines in sputum are useful markers of the activity of lung disease in cystic fibrosis (CF). Tumour necrosis factor alpha (TNF-alpha) and interleukin-8 (IL-8) concentrations in sputum of 10 CF patients were determined during exacerbation and IL-8 in sputum of 48 patients at a yearly follow-up when patients were in optimal clinical condition. In 9 patients of the former group, TNF-alpha levels were increased during exacerbation. In 4 patients, the peak occurred within 2 d (median value > 1500 ng/l), whereas the remaining 5 had peak values on days 3-6 (median value 720 ng/l). IL-8 levels were > 800 microg/l in all 10 patients, and in 9 cases there was a positive correlation between IL-8 and TNF-alpha. Baseline IL-8 levels of 48 patients showed considerable variation (median 207 microg/l, range 1.5-392). There was a significant correlation between IL-8 concentrations and current colonization with either Pseudomonas aeruginosa or Staphylococcus aureus in the lower airways (p = 0.002), immunoglobulin G levels (p = 0.02) and the severity of the pathological findings shown by chest X-ray (p = 0.008). High IL-8 and TNF-alpha values correlated with symptoms of deterioration. IL-8 levels seemed to be markers of both current bacterial colonization and the degree of lung damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716082     DOI: 10.1080/00365540050164263

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  14 in total

1.  TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis.

Authors:  Cyntia Aac Coutinho; Fernando Al Marson; Aline Rb Marcelino; Luciana C Bonadia; Marcelo P Carlin; Antonio F Ribeiro; Jose D Ribeiro; Carmen S Bertuzzo
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

Review 2.  Human airway mucin glycosylation: a combinatory of carbohydrate determinants which vary in cystic fibrosis.

Authors:  G Lamblin; S Degroote; J M Perini; P Delmotte; A Scharfman; M Davril; J M Lo-Guidice; N Houdret; V Dumur; A Klein; P Rousse
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 3.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

4.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 5.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

6.  Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease.

Authors:  Milene T Saavedra; Grant J Hughes; Linda A Sanders; Michelle Carr; David M Rodman; Christopher D Coldren; Mark W Geraci; Scott D Sagel; Frank J Accurso; James West; Jerry A Nick
Journal:  Am J Respir Crit Care Med       Date:  2008-08-21       Impact factor: 21.405

7.  Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis.

Authors:  A P Watt; V Brown; J Courtney; M Kelly; L Garske; J S Elborn; M Ennis
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

8.  Impairment in inflammasome signaling by the chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients results in an increase in inflammatory response.

Authors:  Melissa S Phuong; Rafael E Hernandez; Daniel J Wolter; Lucas R Hoffman; Subash Sad
Journal:  Cell Death Dis       Date:  2021-03-04       Impact factor: 8.469

Review 9.  CFTR activity and mitochondrial function.

Authors:  Angel Gabriel Valdivieso; Tomás A Santa-Coloma
Journal:  Redox Biol       Date:  2013-02-05       Impact factor: 11.799

10.  Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.

Authors:  Tayyab Rehman; Philip H Karp; Ping Tan; Brian J Goodell; Alejandro A Pezzulo; Andrew L Thurman; Ian M Thornell; Samantha L Durfey; Michael E Duffey; David A Stoltz; Edward F McKone; Pradeep K Singh; Michael J Welsh
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.